Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invitrogen Herceptin candidate Dx launches

This article was originally published in The Gray Sheet

Executive Summary

Firm taps Biocare Medical to distribute its SPOT-Light HER2 test. The kit was PMA approved July 8 for use as an aid to assess which breast cancer patients might benefit from treatment with Genentech's Herceptin therapy (1"The Gray Sheet" July 14, 2008, p. 17). "Working with the Biocare sales force, we believe we will be able to more rapidly and efficiently deliver this critical diagnostic," Invitrogen said

You may also be interested in...



Invitrogen: New Herceptin Candidate Dx Gives More Labs A Chance To Test

Invitrogen's SPOT-Light HER2 test, PMA-approved by FDA July 8, will not be the first kit in the U.S. to help physicians decide if a breast cancer patient will benefit from Genentech's Herceptin therapy, but it will allow a host of new laboratories to perform the analysis, according to the firm

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel